Diagnostic accuracy of amniotic fluid interleukin‐6 for fetal inflammatory response syndrome
Journal of Obstetrics and Gynaecology Research · 2023
DOI: 10.1111/jog.15630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Kana Ohkuma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, National Hospital Organization, Saga National Hospital, Saga, Japan. Hauptthemen laut MEDLINE: Premature Rupture of Fetal Membranes, Chorioamnionitis, Premature Birth. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: AMED, the JSPS KAKENHI, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Aim
This study aimed to clarify the diagnostic accuracy of amniotic fluid interleukin‐6 for fetal inflammatory response syndrome (FIRS).
Methods
This retrospective cohort study was conducted in a single institution and targeted cases of preterm birth within 24 h after amniocentesis among singleton cases that underwent amniocentesis at our hospital for suspected intraamniotic inflammation (IAI) from gestational ages of 22–36 weeks between August 2014 and March 2020. FIRS was defined as >11.0 pg/mL of umbilical cord blood interleukin‐6.
Results
The analysis included 158 pregnant women. There was a strong correlation between amniotic fluid interleukin‐6 and umbilical cord blood interleukin‐6 ( r = 0.70, p < 0.001). The area under the receiver operating characteristic curve of amniotic fluid interleukin‐6 for FIRS was 0.93, with a cutoff value of 15.5 ng/mL, and showed high sensitivity and specificity (0.91 and 0.88, respectively). An amniotic fluid interleukin‐6 cutoff value of ≥15.5 ng/mL was associated with a significant risk of FIRS (adjusted odds ratio: 27.9; 95% confidence interval: 6.3–123.0; p < 0.001).
Conclusions
The results of this study show that amniotic interleukin 6 alone can be used to diagnose FIRS prenatally. While there is a need for validation, it may be possible to treat IAI while preventing damage to the central nervous and respiratory systems in the uterus by keeping the amniotic fluid interleukin‐6 below the cutoff value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, National Hospital Organization, Saga National Hospital, Saga, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Saga University, Saga, Japan.
- Department of Pathology, Japan Community Health Care Organization, Saga Central Hospital, Saga, Japan.
- Department of Developmental Medicine, Research Institute, Osaka Women's and Children's Hospital, Osaka, Japan.
ORCID-Profile: Itaru Yanagihara, Makoto Nomiyama
Förderung
- AMED
- the JSPS KAKENHI
- Japan Agency for Medical Research and Development
Zitieren
APA
Ohkuma, K., Ono, T., Oshima, Y., So, K., Tsumura, K., Yamasaki, F., Nakura, Y., Yanagihara, I., Nomiyama, M., & Yokoyama, M. (2023). Diagnostic accuracy of amniotic fluid interleukin‐6 for fetal inflammatory response syndrome. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15630
Vancouver
Ohkuma K, Ono T, Oshima Y, So K, Tsumura K, Yamasaki F, et al. Diagnostic accuracy of amniotic fluid interleukin‐6 for fetal inflammatory response syndrome. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15630
BibTeX
@article{Ohkuma2023,
author = {Ohkuma, Kana and Ono, Takeshi and Oshima, Yuko and So, Kunio and Tsumura, Keisuke and Yamasaki, Fumio and Nakura, Yukiko and Yanagihara, Itaru and Nomiyama, Makoto and Yokoyama, Masatoshi},
title = {Diagnostic accuracy of amniotic fluid interleukin‐6 for fetal inflammatory response syndrome},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
doi = {10.1111/jog.15630}
}
EUVIMED